Biotin

證據等級: L5

預測適應症: 2 個

Biotin: From Nutritional Supplement to Dyspepsia

One-Sentence Summary

Biotin (Vitamin B7) is an essential water-soluble coenzyme used primarily as a nutritional supplement for biotin deficiency and metabolic support. The TxGNN model predicts it may have potential utility in Dyspepsia, with 2 clinical trials (both of low direct relevance) and 7 publications (largely indirect) identified to date. No biotin pharmaceutical products are currently licensed in Canada, and direct clinical evidence for this indication is absent.

Quick Overview

Item	Content
Original Indication	Nutritional supplement — Vitamin B7 / biotin deficiency
Predicted New Indication	Dyspepsia
TxGNN Prediction Score	99.43%
Evidence Level	L4
Canada Market Status	Not marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Biotin (Vitamin B7) is an essential cofactor for multiple carboxylase enzymes involved in fatty acid synthesis, gluconeogenesis, and amino acid catabolism. Biotin deficiency is well documented to produce gastrointestinal symptoms—including nausea, vomiting, and abdominal bloating—that overlap substantially with the clinical presentation of dyspepsia. The theoretical basis for the TxGNN prediction is that correcting an underlying biotin deficiency could alleviate metabolism-related gastrointestinal dysfunction.

However, this mechanistic link is highly indirect and requires several unverified assumptions: that the dyspepsia in question is caused or substantially worsened by biotin deficiency, and that replenishing biotin would correct the relevant metabolic disturbance. In practice, functional dyspepsia is a multifactorial condition with diverse etiologies—including Helicobacter pylori infection, gastric motility disorders, visceral hypersensitivity, and gut–brain axis dysregulation—in which biotin deficiency plays no established causal role.

Currently, detailed mechanism of action data is not available from the source dataset. Based on known biochemistry, biotin’s role as a carboxylase cofactor provides a plausible but unconfirmed rationale for gastrointestinal symptom modulation. The available literature captures co-occurrence rather than causation: one case report documented biotin deficiency arising in an infant who had been diagnosed with dyspepsia on an amino acid formula, and one supplement trial evaluated a multi-ingredient product containing biotin for functional dyspepsia—but neither isolates biotin’s individual contribution. The prediction is biologically speculative and lacks a direct experimental evidence chain.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03360435	N/A	Completed	99	Observed serum micronutrient concentrations (potentially including biotin) after transdermal patch use in post-bariatric surgery patients; primary endpoint is absorption kinetics, not dyspepsia treatment
NCT05389813	Phase 2/3	Unknown	150	Compared oxycodone vs. pregabalin for postoperative pain control in elective surgery patients; no connection to biotin or dyspepsia

Note: Neither trial investigates biotin’s efficacy in dyspepsia. Both were retrieved as low-relevance search results and should not be interpreted as supporting evidence for this repurposing hypothesis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25384804	2014	Clinical Observation	Minerva Gastroenterol Dietol	Multi-ingredient supplement (sodium alginate, calcium carbonate, enzymes, ginger, fennel, and biotin) improved quality of life in functional dyspepsia after H. pylori eradication; biotin’s individual contribution cannot be isolated from the combination
15863846	2005	Case Report	J Dermatology	5-month-old infant diagnosed with dyspepsia and fed only amino acid formula subsequently developed classic biotin deficiency (alopecia, dermatitis); establishes co-occurrence, not a causal treatment relationship
21695955	2011	Intervention Study	Exp Clin Gastroenterol	Supplement containing inulin, oligofructose, biotin, and other vitamins improved gut microbiota in patients with bronchopulmonary disease on antibiotics; GI relevance is indirect
25110039	2014	Cross-Sectional Study	Int J Mol Med	Characterised stomach antral endocrine cell populations in IBS patients vs. healthy controls; no connection to biotin
24891930	2014	Cross-Sectional Study	World J Gastrointest Endosc	Studied endocrine cell types in the oxyntic mucosa of IBS patients; no connection to biotin

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score (99.43%), no clinical trial directly investigates biotin for dyspepsia, and the retrieved literature provides only indirect or incidental associations. The mechanistic hypothesis—that biotin supplementation corrects metabolism-driven gastrointestinal dysfunction—is biologically plausible but entirely unverified, placing this candidate firmly at the preclinical hypothesis stage (L4). With zero licensed products in Canada and no safety profile data available, advancement is not yet warranted.

To proceed, the following is needed:

Retrieve mechanism of action (MOA) data from DrugBank (DB00121) to formally characterise biotin’s carboxylase pathways and their relevance to gastric physiology
Commission a targeted preclinical study or hypothesis-driven systematic review examining the biotin–gut motility axis
Obtain safety profile data (key warnings, contraindications, DDI profile) from the package insert or Health Canada databases
Conduct a dedicated clinical literature search using MeSH terms combining “biotin” with “functional dyspepsia,” “gastrointestinal motility,” and “gastric emptying” to rule out missed evidence
If a plausible patient subgroup can be defined (e.g., dyspepsia with confirmed biotin deficiency or post-bariatric surgery malabsorption), consider a proof-of-concept pilot study design
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.